FDA Gives Green Light to Test Lyme Disease Vaccine on Humans

[Henriëtte]

Wickipedia

Er wordt door farmaceuten gewerkt aan tweede generatie vaccins tegen lyme, maar deze zijn nog niet leverbaar. Tegelijkertijd wordt er onderzoek gedaan naar het immuun maken van dragers van de bacterie, met name knaagdieren. Als deze dieren de bacterie niet langer meer dragen, kunnen teken hem niet meer overdragen. Testen met muizen waarbij deze voer met daarin vaccin te eten kregen, bleken in 89% immuun te worden. Er wordt zelfs gewerkt aan gemodificeerde rijstplanten die het vaccin bevatten en aan muizen gevoerd kunnen worden. Een weer iets andere - veelbelovende - benadering is het besmetten van muizen met een aangepast virus dat hen ongevoelig maakt voor Borrelia, om op die manier de levenscyclus van de bacterie te doorbreken.[16]

Henriëtte

[VerlorengezondheidM]

Naar alles waar een buidel met geld boven hangt wordt onderzoek gedaan!

Henriëtte

Inderdaad follow the money (and the power)

[VerlorengezondheidM]

Schatgraven in speeksel

Bron: AMC, lees meer

[VerlorengezondheidM]

Schatgraven in speeksel

Bron: AMC, lees meer

Counterattacking the tick bite: towards a rational design of anti-tick vaccines targeting pathogen transmission

Ryan O. M. Rego, Jos J. A. Trentelman, […]Joppe W. Hovius

Bron: parasitesandvectors.biomedcentral.com, lees meer

[VerlorengezondheidM]

The Vaccine Reaction

An enlightened conversation about vaccination, health and autonomy

FDA Gives Green Light to Test Lyme Disease Vaccine on Humans
by Patrice La Vigne and Barbara Loe Fisher
Published January 26, 2017

http://www.thevaccinereaction.org/2017/ ... on-humans/

Clinical trials for a new Lyme disease vaccine will be conducted in the U.S. and Belgium after the U.S. Food and Drug Administration (FDA) and European Union’s Clinical Trial Application gave Biotech firm Valneva of France clearance to begin Phase I testing.1

Valneva is developing VLA15, a hexavalent, protein subunit-based vaccine for protection against Lyme’s disease, a tick-transmitted bacterial infection characterized by fever, headache, fatigue and skin rash that, if left untreated, can spread to the joints, heart and nervous system and cause severe, chronic health problems.2 The vaccine targets the outer surface protein A (OspA), one of the most dominant antigens expressed by the Borrelia bacteria transmitted by a tick.1

The serotypes expressed by the U.S. species of the Borrelia bacteria differ from the European version of the bacteria. In fact, there are six types of the proteins. Valneva’s vaccine aims to target all different strains of OspA and teach the body’s immune system to recognize the bacteria and launch an attack.3

First Lyme Vaccine Withdrawn After Injury Claims

This is not the first time a company has pursued a Lyme disease vaccine candidate, although there are no vaccines currently on the market.

In 1998, the FDA approved LYMErix, manufactured by SmithKline Beecham (now GlaxoSmithKline) of the United Kingdom. Patients received three doses of the vaccine, which was manufactured using a recombinant Burellia burgdorferi outer surface protein (OspPA). The company claimed an effectiveness rate of 80 percent.

However, almost immediately after the vaccine was licensed and distributed, there were complaints that LYMErix vaccine was causing Lyme disease symptoms and in some cases was causing permanently disabling brain and immune system damage, including treatment resistant autoimmune arthritis.
[.....]

Lyme disease vaccine found to be safe and effective in clinical trial

By Alice Klein

A vaccine against Lyme disease has been shown to be safe and effective in a clinical trial and could be available by 2025.

Tens of thousands of people in the US and Europe are diagnosed each year with Lyme disease, which is transmitted by tick bites and can cause lifelong health problems like joint and nerve pain if it isn’t treated early.

French company Valneva has developed a vaccine that works by stopping Lyme-causing bacteria in ticks from passing into people’s bloodstreams when the ticks bite.

Bron: Newscientist, lees meer: https://www.newscientist.com/article/22 ... z6TxvKlVA0

[VerlorengezondheidM]

Frankrijk werkt aan vaccin tegen Lyme

Geschreven door:
René Steenhorst

Biotechbedrijf start omvangrijke tests met entstof bij kinderen en volwassenen

Bron: meerovermedisch.nl, lees meer